You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
24 November 2020
MetrioPharm AG: COVID-19 Therapeutic Agent: MetrioPharm Prepares to Conduct a Phase II Clinical Trial
5 November 2020
MetrioPharm AG: MetrioPharm Announces Publication of Successful MP1032 Preclinical Data in COVID-19
8 April 2020
MetrioPharm AG: MetrioPharm Successfully Completes Study in COPD Model
16 October 2019
MetrioPharm AG: MetrioPharm AG Phase II Data in Psoriasis Show Dose-Response, Disease Modifying Activity and Outstanding Safety Profile
23 July 2019
MetrioPharm AG: Sven Zimmermann Joins MetrioPharm Management as CFO
17 June 2019
MetrioPharm AG: Last Patient Last Visit in MetrioPharm’s Phase II Clinical Trial in Psoriasis
16 May 2019
MetrioPharm AG: MetrioPharm AG Publishes Annual Report for 2018
10 April 2019
MetrioPharm AG: Barry Frankel is new Senior Vice President Strategy and Business Development of MetrioPharm AG
26 February 2019
MetrioPharm AG: MetrioPharm Enrolls Last Patient in Phase II Study on MP1032 in Psoriasis
19 February 2019
MetrioPharm AG: MetrioPharm CEO Dr. Brysch as Panel Speaker at the European Life Science CEO Forum
11 December 2018
MetrioPharm AG: MetrioPharm AG Closes Financing Round of CHF 20 Million
15 November 2018
MetrioPharm AG: MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Canada
9 October 2018
MetrioPharm AG: MetrioPharm Announces Presentation of Preclinical Data on MP1032 in Multiple Sclerosis Therapy at ECTRIMS Congress 2018
14 August 2018
MetrioPharm AG: MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinical Trial
26 June 2018
MetrioPharm AG: MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at the 5th WPPAC in Stockholm
7 March 2018
MetrioPharm AG: First patient dosed in a clinical Phase II trial for MP1032 for the treatment of moderate-to-severe chronic plaque psoriasis
14 March 2017
MetrioPharm Announces Positive Top-Line Results from a Phase IIa Study in Moderate-to-Severe Psoriasis with its Oral Lead Compound MP1032
18 March 2010
MetrioPharm extends drug pipeline to cancer therapy
4 March 2010
MetrioPharm AG announces capital increase
27 November 2009
Conversion of bearer shares to registered shares
8 June 2009
MetrioPharm AG has published financial figures 2008
8 May 2009
MetrioPharm AG initiates development program for emergency medication against epidemic infections
16 March 2009
MetrioPharm AG: New study confirms high efficacy of MP1021
2 March 2009
MetrioPharm AG: MetrioPharm AG files new patent for MP1021
23 September 2008
MetrioPharm AG: Realignment in financial communications
9 September 2008
MetrioPharm AG: Gegendarstellung
